Karol Adam Kaminski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6924509/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment goal attainment for secondary prevention in coronary patients with or without diabetes mellitus – Polish multicenter study POLASPIRE. Archives of Medical Science, 2023, 19, 305-312.	0.9	5
2	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). Journal of Affective Disorders, 2022, 299, 367-376.	4.1	33
3	Novel associations between inflammation-related proteins and adiposity: A targeted proteomics approach across four population-based studies. Translational Research, 2022, 242, 93-104.	5.0	13
4	Dietary Total Antioxidant Capacity Is Inversely Associated with Prediabetes and Insulin Resistance in Bialystok PLUS Population. Antioxidants, 2022, 11, 283.	5.1	9
5	Effectiveness of Lifestyle Modification vs. Therapeutic, Preventative Strategies for Reducing Cardiovascular Risk in Primary Prevention—A Cohort Study. Journal of Clinical Medicine, 2022, 11, 688.	2.4	5
6	Why Do These Microbes Like Me and How Could There Be a Link with Cardiovascular Risk Factors?. Journal of Clinical Medicine, 2022, 11, 599.	2.4	0
7	Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. European Heart Journal, 2022, 43, 1715-1727.	2.2	40
8	Oral Health–Related Quality of Life and Missing Teeth in an Adult Population: A Cross-Sectional Study from Poland. International Journal of Environmental Research and Public Health, 2022, 19, 1626.	2.6	8
9	Voice changes in reproductive disorders, thyroid disorders and diabetes: a review. Endocrine Connections, 2022, 11, .	1.9	5
10	IGFBP7 Concentration May Reflect Subclinical Myocardial Damage and Kidney Function in Patients with Stable Ischemic Heart Disease. Biomolecules, 2022, 12, 274.	4.0	2
11	Factors Associated with Tooth Loss in General Population of Bialystok, Poland. International Journal of Environmental Research and Public Health, 2022, 19, 2369.	2.6	10
12	Analysis of Clinical Course and Vaccination Influence on Serological Response in COVID-19 Convalescents. Microbiology Spectrum, 2022, , e0248521.	3.0	0
13	Body Composition and Serum Concentration of Thyroid Hormones in Euthyroid Men and Women from General Population. Journal of Clinical Medicine, 2022, 11, 2118.	2.4	2
14	The relationships between FLAIS, a novel insulin sensitivity index, and cardiovascular risk factors in a population-based study. Cardiovascular Diabetology, 2022, 21, 55.	6.8	0
15	ECG in the clinical and prognostic evaluation of patients with pulmonary arterial hypertension: an underestimated value. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662210878.	2.6	6
16	Platelet sTWEAK and plasma IL-6 are associated with 18F-fluorodeoxyglucose uptake in right ventricles of patients with pulmonary arterial hypertension: A pilot study. Advances in Clinical and Experimental Medicine, 2022, 31, 991-998.	1.4	4
17	Insulin-Like Growth Factor-Binding Protein 7 (IGFBP-7)—New Diagnostic and Prognostic Marker in Symptomatic Peripheral Arterial Disease?—Pilot Study. Biomolecules, 2022, 12, 712.	4.0	1
18	COVID-19Âpandemic influence onÂself-reported health status and well-beingÂinÂaÂsociety. Scientific Reports. 2022. 12	3.3	4

#	Article	IF	CITATIONS
19	Recollection of Physician Information about Risk Factor and Lifestyle Changes in Chronic Coronary Syndrome Patients. International Journal of Environmental Research and Public Health, 2022, 19, 6416.	2.6	1
20	Trained Immunity as a Trigger for Atherosclerotic Cardiovascular Disease—A Literature Review. Journal of Clinical Medicine, 2022, 11, 3369.	2.4	4
21	Impact of the COVID-19 Pandemic on Pulmonary Hypertension Patients: Insights from the BNP-PL National Database. International Journal of Environmental Research and Public Health, 2022, 19, 8423.	2.6	5
22	Prognostic role of PET/MRI hybrid imaging in patients with pulmonary arterial hypertension. Heart, 2021, 107, 54-60.	2.9	12
23	Prognostic value of late gadolinium enhancement mass index in patients with pulmonary arterial hypertension. Advances in Medical Sciences, 2021, 66, 28-34.	2.1	7
24	Characteristics and outcomes of patients with chronic thromboembolic pulmonary hypertension in the era of modern therapeutic approaches: data from the Polish multicenter registry (BNP-PL). Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110029.	2.5	21
25	Smoking cessation in patients with established coronary artery disease: data from the POLASPIRE survey. Kardiologia Polska, 2021, 79, 418-425.	0.6	3
26	A Similar Lifetime CV Risk and a Similar Cardiometabolic Profile in the Moderate and High Cardiovascular Risk Populations: A Population-Based Study. Journal of Clinical Medicine, 2021, 10, 1584.	2.4	14
27	Effects of cardiac rehabilitation on risk factor management and quality of life in patients with ischemic heart disease: A multicenter cross-sectional study. Polish Archives of Internal Medicine, 2021, 131, 617-625.	0.4	2
28	Multimodal assessment of right ventricle overload-metabolic and clinical consequences in pulmonary arterial hypertension. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 49.	3.3	11
29	Undiagnosed Diabetes and Prediabetes in Patients with Chronic Coronary Syndromes—An Alarming Public Health Issue. Journal of Clinical Medicine, 2021, 10, 1981.	2.4	1
30	Management of Dyslipidemia in Women and Men with Coronary Heart Disease: Results from POLASPIRE Study. Journal of Clinical Medicine, 2021, 10, 2594.	2.4	4
31	Echocardiographic Assessment of Right Ventricular–Arterial Coupling in Predicting Prognosis of Pulmonary Arterial Hypertension Patients. Journal of Clinical Medicine, 2021, 10, 2995.	2.4	14
32	Effectiveness and safety of a simple home-based rehabilitation program in pulmonary arterial hypertension: an interventional pilot study. BMC Sports Science, Medicine and Rehabilitation, 2021, 13, 79.	1.7	8
33	Serum Chemerin Concentration Is Associated with Proinflammatory Status in Chronic Coronary Syndrome. Biomolecules, 2021, 11, 1149.	4.0	7
34	COVID-19 Vaccine Hesitancy in Poland—Multifactorial Impact Trajectories. Vaccines, 2021, 9, 876.	4.4	47
35	Gut Microbiome in Chronic Coronary Syndrome Patients. Journal of Clinical Medicine, 2021, 10, 5074.	2.4	13
36	Subjective well-being in non-obese individuals depends strongly on body composition. Scientific Reports, 2021, 11, 21797.	3.3	10

KAROL ADAM KAMINSKI

#	Article	IF	CITATIONS
37	Which Microbes Like My Diet and What Does It Mean for My Heart?. Nutrients, 2021, 13, 4146.	4.1	3
38	Monocyte Subsets in Patients with Chronic Heart Failure Treated with Cardiac Resynchronization Therapy. Cells, 2021, 10, 3482.	4.1	3
39	Independent Impact of Gynoid Fat Distribution and Free Testosterone on Circulating Levels of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) in Humans. Journal of Clinical Medicine, 2020, 9, 74.	2.4	12
40	Machine-learning facilitates selection of a novel diagnostic panel of metabolites for the detection of heart failure. Scientific Reports, 2020, 10, 130.	3.3	9
41	Chemokines profile in patients with chronic heart failure treated with cardiac resynchronization therapy. Advances in Medical Sciences, 2020, 65, 102-110.	2.1	4
42	The effect of interleukin 6 deficiency on myocardial signal transduction pathways activation induced by bacterial lipopolysaccharide in young and old mice. Advances in Medical Sciences, 2020, 65, 386-393.	2.1	1
43	Impact of Pulse Wave Velocity and Parameters Reflecting Android Type Fat Distribution on Left Ventricular Diastolic Dysfunction in Patients with Chronic Coronary Syndromes. Journal of Clinical Medicine, 2020, 9, 3924.	2.4	5
44	Effects of neurohormonal antagonists on blood pressure in patients with heart failure with reduced ejection fraction (HFrEF): a systematic review protocol. Systematic Reviews, 2020, 9, 194.	5.3	0
45	Expectations of family nurses among residents of a midsize eastern European city: A populationâ€based cohort study in Poland. Health and Social Care in the Community, 2020, , .	1.6	Ο
46	Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	2.8	4,468
47	ECG Indices Poorly Predict Left Ventricular Hypertrophy and Are Applicable Only in Individuals with Low Cardiovascular Risk. Journal of Clinical Medicine, 2020, 9, 1364.	2.4	5
48	Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study. Journal of Clinical Medicine, 2020, 9, 1640.	2.4	6
49	Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL). Journal of Clinical Medicine, 2020, 9, 173.	2.4	38
50	Association between rs2107595 HDAC9 gene polymorphism and advanced carotid atherosclerosis in the Slovenian cohort. Lipids in Health and Disease, 2020, 19, 71.	3.0	6
51	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 study. Atherosclerosis Supplements, 2020, 42, e15-e24.	1.2	18
52	Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. Cardiology Journal, 2020, 27, 533-540.	1.2	18
53	Altered microRNA dynamics in acute coronary syndrome. Postepy W Kardiologii Interwencyjnej, 2020, 16, 287-293.	0.2	5
54	Association of Empirical Dietary Atherogenic Indices with All-Cause and Cause-Specific Mortality in a Multi-Ethnic Adult Population of the United States, Nutrients, 2019, 11, 2323	4.1	14

KAROL ADAM KAMINSKI

#	Article	IF	CITATIONS
55	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis, 2019, 285, 135-146.	0.8	227
56	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
57	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	3.6	22
58	Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart disease. Advances in Medical Sciences, 2019, 64, 195-201.	2.1	14
59	P4686Multimodal assessment of right ventricular-arterial coupling allows better prognostication in pulmonary arterial hypertension patients. European Heart Journal, 2019, 40, .	2.2	0
60	The role of interleukin-6 in intracellular signal transduction after chronic β-adrenergic stimulation in mouse myocardium. Archives of Medical Science, 2019, 15, 1565-1575.	0.9	11
61	Fluid therapy in non-septic, refractory acute decompensated heart failure patients – The cautious role of central venous pressure. Advances in Medical Sciences, 2019, 64, 37-43.	2.1	2
62	The relationships among monocyte subsets, miRNAs and inflammatory cytokines in patients with acute myocardial infarction. Pharmacological Reports, 2019, 71, 73-81.	3.3	16
63	Increased platelet content of SDF-1alpha is associated with worse prognosis in patients with pulmonary prterial hypertension. Platelets, 2019, 30, 445-451.	2.3	8
64	Interleukin 6 Knockout Inhibits Aging-Related Accumulation of p53 in the Mouse Myocardium. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 176-182.	3.6	8
65	Database of Pulmonary Hypertension in the Polish Population (BNP‑PL): design of the registry. Kardiologia Polska, 2019, 77, 972-974.	0.6	18
66	Insulin-like growth factor-binding protein 7 (IGFBP7): Novel, independent marker of cardiometabolic diseases?. Postepy Higieny I Medycyny Doswiadczalnej, 2019, 73, 735-740.	0.1	3
67	Sarcopenia and myokines profile as risk factors in cardiovascular diseases?. Postepy Higieny I Medycyny Doswiadczalnej, 2019, 73, 550-562.	0.1	0
68	LC–MS-based serum fingerprinting reveals significant dysregulation of phospholipids in chronic heart failure. Journal of Pharmaceutical and Biomedical Analysis, 2018, 154, 354-363.	2.8	26
69	The significance of diminished sTWEAK and P-selectin content in platelets of patients with pulmonary arterial hypertension. Cytokine, 2018, 107, 52-58.	3.2	8
70	Perioperative thrombocytopenia predicts poor outcome in patients undergoing transcatheter aortic valve implantation. Advances in Medical Sciences, 2018, 63, 179-184.	2.1	9
71	P1630Myocardial late gadolinium enhancement mass and FDG uptake assessments using a hybrid PET/MRI system in patients with pulmonary arterial hypertension. European Heart Journal, 2018, 39, .	2.2	0
72	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	13.7	4,989

#	Article	IF	CITATIONS
73	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	13.7	8,569
74	Persistently elevated plasma heart-type fatty acid binding protein concentration is related with poor outcome in acute decompensated heart failure patients. Clinica Chimica Acta, 2018, 487, 48-53.	1.1	11
75	1098Machine learning facilitates selecting a group of metabolites non-inferior to BNP for the diagnosis of chronic heart failure. European Heart Journal, 2018, 39, .	2.2	Ο
76	P6337IL-6 plasma concentration is associated with right ventricular myocardial 18-F glucose uptake, but not functional RV parameters obtained by MRI in patients with pulmonary arterial hypertension. European Heart Journal, 2018, 39, .	2.2	0
77	Very Small Embryonic-Like Stem Cells, Endothelial Progenitor Cells, and Different Monocyte Subsets Are Effectively Mobilized in Acute Lymphoblastic Leukemia Patients after G-CSF Treatment. Stem Cells International, 2018, 2018, 1-8.	2.5	9
78	The role of platelets in the development and progression of pulmonary arterial hypertension. Advances in Medical Sciences, 2018, 63, 312-316.	2.1	22
79	Interleukin-6 deficiency modifies the effect of high fat diet on myocardial expression of fatty acid transporters and myocardial lipids. Journal of Physiology and Pharmacology, 2018, 69, .	1.1	3
80	Decreased thromboembolic stroke but not atherosclerosis or vascular remodelling in mice with ROCK2-deficient platelets. Cardiovascular Research, 2017, 113, 1307-1317.	3.8	22
81	The causes of thrombocytopenia after transcatheter aortic valve implantation. Thrombosis Research, 2017, 156, 39-44.	1.7	20
82	Thrombocytopenia associated with TAVI—The summary of possible causes. Advances in Medical Sciences, 2017, 62, 378-382.	2.1	20
83	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2017, 32, 1967-1976.	0.7	14
84	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
85	Interleukin-6 Affects Aging-Related Changes of the PPARα-PGC-1α Axis in the Myocardium. Journal of Interferon and Cytokine Research, 2017, 37, 513-521.	1.2	9
86	The strengths and weaknesses of non-invasive parameters obtained by echocardiography and cardiopulmonary exercise testing in comparison with the hemodynamic assessment by the right heart catheterization in patients with pulmonary hypertension. Advances in Medical Sciences, 2017, 62, 39-44.	2.1	9
87	Interleukin-6 signaling in patients with chronic heart failure treated with cardiac resynchronization therapy. Archives of Medical Science, 2017, 5, 1069-1077.	0.9	16
88	The rs2228145 polymorphism in the interleukin-6 receptor and its association with long-term prognosis after myocardial infarction in a pilot study. Archives of Medical Science, 2017, 1, 93-99.	0.9	3
89	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2017, 75, 286-293.	0.6	0
90	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2017, 75, 33-41.	0.6	0

KAROL ADAM KAMINSKI

#	Article	IF	CITATIONS
91	Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure. Cytokine, 2016, 80, 7-12.	3.2	27
92	Interleukin 6 modulates PPARα and PGC-1α and is involved in high-fat diet induced cardiac lipotoxicity in mouse. International Journal of Cardiology, 2016, 219, 1-8.	1.7	21
93	Metabolomics — A wide-open door to personalized treatment in chronic heart failure?. International Journal of Cardiology, 2016, 219, 156-163.	1.7	28
94	The influence of renal function on the association of rs854560 polymorphism of paraoxonase 1 gene with long-term prognosis in patients after myocardial infarction. Heart and Vessels, 2016, 31, 15-22.	1.2	8
95	Activity of the kynurenine pathway and its interplay with immunity in patients with pulmonary arterial hypertension. Heart, 2016, 102, 230-237.	2.9	28
96	Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. Atherosclerosis, 2016, 246, 309-317.	0.8	49
97	Remodeling of the intercalated disc related to aging in the mouse heart. Journal of Cardiology, 2016, 68, 261-268.	1.9	42
98	The 9p21 polymorphism is linked with atrial fibrillation during acute phase of ST-segment elevation myocardial infarction. Heart and Vessels, 2016, 31, 1590-1594.	1.2	3
99	Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiologia Polska, 2016, 74, 213-223.	0.6	37
100	A study to evaluate the prevalence and determinants of stress coping strategies in heart failure patients in Poland (CAPS-LOCK-HF sub-study). Kardiologia Polska, 2016, 74, 1327-1331.	0.6	3
101	The rs12526453 Polymorphism in an Intron of the PHACTR1 Gene and Its Association with 5-Year Mortality of Patients with Myocardial Infarction. PLoS ONE, 2015, 10, e0129820.	2.5	15
102	Circulating classical CD14++CD16â^' monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163. Oncology Reports, 2015, 34, 1269-1278.	2.6	16
103	Differential involvement of IL-6 in the early and late phase of 1-methylnicotinamide (MNA) release in Concanavalin A-induced hepatitis. International Immunopharmacology, 2015, 28, 105-114.	3.8	21
104	The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension. International Journal of Molecular Sciences, 2015, 16, 10715-10733.	4.1	33
105	Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. Cytokine, 2015, 76, 187-192.	3.2	36
106	Transcriptional and post-transcriptional regulation of CCN genes in failing heart. Pharmacological Reports, 2015, 67, 204-208.	3.3	9
107	The rs9982601 polymorphism of the region between the SLC5A3/MRPS6 and KCNE2 genes associated with a prevalence of myocardial infarction and subsequent long-term mortality. Polish Archives of Internal Medicine, 2015, 125, 240-248.	0.4	10
108	Clinical significance of measuring inflammatory markers in patients with pulmonary arterial hypertension. Authors' reply. Polish Archives of Internal Medicine, 2015, 125, 216-216.	0.4	0

Karol Adam Kaminski

#	Article	IF	CITATIONS
109	CHA2DS2-VASc and R2CHA2DS2-VASc scores have predictive value in patients with acute coronary syndromes. Polish Archives of Internal Medicine, 2015, 125, 545-552.	0.4	13
110	Clinical significance of measuring inflammatory markers in patients with pulmonary arterial hypertension. Authors' reply. , 2015, 125, 216.		0
111	Polymorphism of 9p21.3 Locus Is Associated with 5-Year Survival in High-Risk Patients with Myocardial Infarction. PLoS ONE, 2014, 9, e104635.	2.5	12
112	<scp>ESC</scp> Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models. European Journal of Heart Failure, 2014, 16, 509-518.	7.1	11
113	PPAR Gamma Expression Levels during Development of Heart Failure in Patients with Coronary Artery Disease after Coronary Artery Bypass-Grafting. PPAR Research, 2014, 2014, 1-5.	2.4	6
114	Lipid, blood pressure and kidney update 2013. International Urology and Nephrology, 2014, 46, 947-961.	1.4	60
115	Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension. Cytokine, 2014, 66, 40-45.	3.2	26
116	Natural history and risk factors of long-term mortality in acute coronary syndrome patients with cardiogenic shock. Advances in Medical Sciences, 2014, 59, 156-160.	2.1	6
117	Running Performance at High Running Velocities Is Impaired but V′O2max and Peripheral Endothelial Function Are Preserved in IL-6â^'/â~' Mice. PLoS ONE, 2014, 9, e88333.	2.5	12
118	Potential pathogenic role of soluble receptor activator of nuclear factor-Äß ligand and osteoprotegerin in patients with pulmonary arterial hypertension. Polish Archives of Internal Medicine, 2014, 124, 579-586.	0.4	3
119	The effects of statins on blood pressure in normotensive or hypertensive subjects — A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2013, 168, 2816-2824.	1.7	37
120	The rs9982601 polymorphism of the intergenic region between SLC5A3/MRPS6/KCNE2 genes is associated with 5-year mortality of patients with ST-elevation myocardial infarction. European Heart Journal, 2013, 34, P1302-P1302.	2.2	0
121	Feasibility of strain and strain rate evaluation by two-dimensional speckle tracking in murine model of myocardial infarction. Journal of Cardiovascular Medicine, 2013, 14, 136-143.	1.5	5
122	Polymorphism of 9p21.3 Locus Is Associated with 5-Year Survival in High-Risk Patients with Myocardial Infarction. PLoS ONE, 2013, 8, e72333.	2.5	7
123	In‑silico identification of cardiovascular disease‑related SNPs affecting predicted microRNA target sites. Polish Archives of Internal Medicine, 2013, 123, 355-369.	0.4	6
124	CCN1 expression in interleukin-6 deficient mouse kidney in experimental model of heart failure. Folia Histochemica Et Cytobiologica, 2013, 51, 84-91.	1.5	11
125	Cardiogenic pulmonary oedema: alarmingly poor long term prognosis. Analysis of risk factors. Kardiologia Polska, 2013, 71, 712-720.	0.6	5
126	Rho-Associated Coiled-Coil-Containing Kinase 2 Deficiency in Bone Marrow–Derived Cells Leads to Increased Cholesterol Efflux and Decreased Atherosclerosis. Circulation, 2012, 126, 2236-2247.	1.6	38

#	Article	IF	CITATIONS
127	Single bout of endurance exercise increases NNMT activity in the liver and MNA concentration in plasma; the role of IL-6. Pharmacological Reports, 2012, 64, 369-376.	3.3	20
128	Interleukin 6 is not necessary for STAT3 phosphorylation and myocardial hypertrophy following short term beta-adrenergic stimulation. Advances in Medical Sciences, 2012, 57, 94-99.	2.1	3
129	The rs1801133 polymorphism of methylenetetrahydrofolate reductase gene- the association with 5-year survival in patients with ST-elevation myocardial infarction. Advances in Medical Sciences, 2012, 57, 106-111.	2.1	6
130	Editorial The effects of statins on blood pressure: current knowledge and future perspectives. Archives of Medical Science, 2012, 1, 1-3.	0.9	10
131	Atrial expression of the CCN1 and CCN2 proteins in chronic heart failure. Folia Histochemica Et Cytobiologica, 2012, 50, 99-103.	1.5	5
132	Atrial expression of the CCN1 and CCN2 proteins in chronic heart failure. Folia Histochemica Et Cytobiologica, 2012, 50, 99-103.	1.5	12
133	GRACE, TIMI, Zwolle and CADILLAC risk scores — Do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively?. International Journal of Cardiology, 2011, 148, 70-75.	1.7	52
134	Hypotensive effect of atorvastatin in hypertensive patients: the association among flow-mediated dilation, oxidative stress and endothelial dysfunction. Archives of Medical Science, 2011, 6, 955-962.	0.9	14
135	Role of interleukin-6 on RANKL-RANK/osteoprotegerin system in hypothyroid ovariectomized mice Folia Histochemica Et Cytobiologica, 2011, 48, 549-54.	1.5	3
136	Efficacy of invasive treatment and the occurrence of cardiac rupture in acute ST-elevation myocardial infarction. Kardiologia Polska, 2011, 69, 795-800.	0.6	6
137	Endothelial dysfunction and sympathetic nervous system activation in young patients with essential arterial hypertension and without hypercholesterolaemia. Acta Cardiologica, 2010, 65, 535-540.	0.9	4
138	Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients – An open, pilot study. Blood Pressure, 2010, 19, 260-266.	1.5	18
139	Circadian variations of interleukin 6 in coronary circulations of patients with myocardial infarction. Cytokine, 2010, 50, 204-209.	3.2	12
140	Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress. Pharmacological Reports, 2010, 62, 883-890.	3.3	11
141	Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients with Stable Angina. Angiology, 2009, 60, 322-328.	1.8	5
142	Relation of Body Mass Index to Five-Year Survival in Patients With ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2009, 103, 435.	1.6	4
143	CCN2 protein is an announcing marker for cardiac remodeling following STZ-induced moderate hyperglycemia in mice. Pharmacological Reports, 2009, 61, 496-503.	3.3	18
144	Coronary sinus concentrations of interleukin 6 and its soluble receptors are affected by reperfusion and may portend complications in patients with myocardial infarction. Atherosclerosis, 2009, 206, 581-587.	0.8	28

#	Article	IF	CITATIONS
145	Effect of interleukin 6 deficiency on the expression of Bcl-2 and Bax in the murine heart. Pharmacological Reports, 2009, 61, 504-513.	3.3	17
146	Time for new indications for statins?. Medical Science Monitor, 2009, 15, MS1-5.	1.1	51
147	Carvedilol modifies antioxidant status of patients with stable angina. Cellular and Molecular Biology Letters, 2008, 13, 230-9.	7.0	12
148	Myocardial perfusion assessed by contrast echocardiography correlates with angiographic perfusion parameters in patients with a first acute myocardial infarction successfully treated with angioplasty. Canadian Journal of Cardiology, 2008, 24, 633-639.	1.7	17
149	Oxidative stress and antioxidative defense parameters early after reperfusion therapy for acute myocardial infarction. Acute Cardiac Care, 2008, 10, 121-126.	0.2	17
150	Lack of ST-Segment Depression Normalization After PCI is a Predictor of 5-Year Mortality in Patients With ST-Elevation Myocardial Infarction. Circulation Journal, 2007, 71, 1851-1856.	1.6	8
151	A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy. Cell, 2007, 128, 589-600.	28.9	736
152	Impairment of recognition memory in interleukin-6 knock-out mice. European Journal of Pharmacology, 2007, 577, 219-220.	3.5	37
153	The association between type 2 diabetes mellitus and A1/A2 polymorphism of glycoprotein IIIa gene. Acta Diabetologica, 2007, 44, 30-33.	2.5	6
154	TIMI Risk Score accurately predicts risk of death in 30-day and one-year follow-up in STEMI patients treated with primary percutaneous coronary interventions. Kardiologia Polska, 2007, 65, 788-95; discussion 796-7.	0.6	8
155	Interleukin-6 is not essential for bone turnover in hypothyroid mice. Folia Histochemica Et Cytobiologica, 2007, 45, 387-92.	1.5	1
156	The effects of moderate physical exercise on cardiac hypertrophy in interleukin 6 deficient mice. Advances in Medical Sciences, 2007, 52, 164-8.	2.1	17
157	Neutrophil Superoxide Anion Generation During Atorvastatin and Fluvastatin Therapy Used in Coronary Heart Disease Primary Prevention. Journal of Cardiovascular Pharmacology, 2006, 48, 143-147.	1.9	37
158	The Benefits of Repeated Measurements of B-type Natriuretic Peptide in Patients With First ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. International Heart Journal, 2006, 47, 843-854.	1.0	4
159	The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Kardiologia Polska, 2006, 64, 1350-5; discussion 1356.	0.6	1
160	Lack of JunD Promotes Pressure Overload–Induced Apoptosis, Hypertrophic Growth, and Angiogenesis in the Heart. Circulation, 2005, 112, 1470-1477.	1.6	60
161	Does gastro-esophageal reflux provoke the myocardial ischemia in patients with CAD?. International Journal of Cardiology, 2005, 104, 67-72.	1.7	44
162	Supraventricular tachycardia and pulmonary hypertension at the presentation of Hodgkin's disease. Acta Cardiologica, 2005, 60, 655-657.	0.9	5

#	Article	IF	CITATIONS
163	Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury. Circulation Research, 2004, 95, 187-195.	4.5	345
164	Regulation of Proangiogenic Factor CCN1 in Cardiac Muscle. Circulation, 2004, 109, 2227-2233.	1.6	104
165	Role of interleukinâ€6 for left ventricular remodeling and survival after experimental myocardial infarction. FASEB Journal, 2003, 17, 1-20.	0.5	113
166	Expression of CYR61, an Angiogenic Immediate Early Gene, in Arteriosclerosis and Its Regulation by Angiotensin II. Circulation, 2002, 106, 254-260.	1.6	103
167	Oxidative stress and neutrophil activation—the two keystones of ischemia/reperfusion injury. International Journal of Cardiology, 2002, 86, 41-59.	1.7	288
168	Diverse effects of prolonged physical training on learning of the delayed non-matching to sample by rats. Neuroscience Research, 2001, 39, 79-84.	1.9	11
169	A 39-Year-Old Woman with Ventricular Electrical Storm Treated with Emergency Cardiac Defibrillation Followed by Multidisciplinary Management. American Journal of Case Reports, 0, 23, .	0.8	2